top_banner
Cancer News

Recent Breast Cancer News
Immunotherapy Offers New Hope in Triple Negative Breast Cancer (December 28, 2018)

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed... Continue Reading

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications (December 21, 2018)

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology... Continue Reading

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer (December 19, 2018)

SAN ANTONIO — Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death... Continue Reading

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer (December 12, 2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual... Continue Reading

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors (December 11, 2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented... Continue Reading

Choice of surgery may affect quality of life for young breast cancer survivors (December 10, 2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research... Continue Reading

20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer (October 31, 2018)

Adjuvant high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant (HSCT) may be beneficial for patients with breast cancer and more than 9 involved axially lymph nodes (ALN), according to... Continue Reading

More women with early-stage breast cancer may be able to avoid chemotherapy (October 10, 2018)

Results from a large clinical trial called TAILORx showed that more women with early-stage breast cancer may now be able to avoid chemotherapy after surgery. The women who participated in the study had... Continue Reading

What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer? (July 25, 2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion... Continue Reading

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer (July 23, 2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor... Continue Reading

Next Page »